...
首页> 外文期刊>The Journal of Urology >Urinary tract infection following successful dextranomer/hyaluronic acid injection for vesicoureteral reflux.
【24h】

Urinary tract infection following successful dextranomer/hyaluronic acid injection for vesicoureteral reflux.

机译:成功注射右旋糖酐/透明质酸用于膀胱输尿管反流后的尿路感染。

获取原文
获取原文并翻译 | 示例
   

获取外文期刊封面封底 >>

       

摘要

PURPOSE: The incidence of symptomatic urinary tract infection following reflux resolution by endoscopic injection is unclear. We determined the occurrence of febrile and nonfebrile urinary tract infections, and factors relating to development of infection after reflux correction with dextranomer/hyaluronic acid injection. MATERIALS AND METHODS: We identified 175 patients with more than 6 months of followup after successful dextranomer/hyaluronic acid injection by one of us (WS) to resolve vesicoureteral reflux. Of these patients data regarding post-injection symptomatic urinary tract infection could be obtained from parents and/or primary care physicians and urological records in 167, who comprised the study group. All patient reported infections were additionally verified by review of medical records. Univariate and multivariate logistic regression analyses were done, evaluating factors including gender, age, voiding dysfunction, reflux grade, unilateral vs bilateral reflux, number of pretreatment infections, number of infections within 12 months of injection and febrile vs nonfebrile urinary tract infection in predicting the likelihood of post-injection urinary tract infection. RESULTS: Urinary tract infection occurred in 159 patients (95%) before injection, and was febrile in 82%. With a median followup after reflux correction of 32 months (range 7 to 53) symptomatic infections developed in 40 children (24%), of which half were febrile. Multivariate analysis showed that the number of preoperative urinary tract infections best predicted the likelihood of infection after dextranomer/hyaluronic acid injection. Nearly half of the patients with febrile urinary tract infection undergoing followup cystography had recurrent reflux. CONCLUSIONS: Patients with more than 3 pre-injection infections were 8.5 times more likely than those with 1 pre-injection infection to have post-injection symptomatic urinary tract infection. Overall rates of symptomatic and febrile infections after dextranomer/hyaluronic acid reflux resolution were similar to those reported following ureteral reimplantation.
机译:目的:内镜下注射反流解决后症状性尿路感染的发生率尚不清楚。我们确定了高热和非高热尿路感染的发生,以及与右旋糖酐/透明质酸注射液反流纠正后感染发展相关的因素。材料与方法:我们确定了175名患者,其中由我们中的一位(WS)成功注射右旋糖酐/透明质酸以解决膀胱输尿管反流,随访时间超过6个月。在这些患者中,有关注射后症状性尿路感染的数据可从构成研究组的167位父母和/或基层医疗医生那里获得,以及泌尿科记录。所有患者报告的感染均通过查阅病历进行了进一步验证。进行了单因素和多因素logistic回归分析,评估因素包括性别,年龄,排尿功能障碍,反流程度,单侧与双侧反流,治疗前感染的次数,注射后12个月内的感染次数以及高热与非高热尿路感染的预测。注射后尿路感染的可能性。结果:注射前有159例患者(占95%)发生了尿路感染,其中82%的患者出现了发热。在反流矫正后的32个月(范围7至53)中位随访中,有40名儿童(24%)出现了症状性感染,其中一半是高热的。多变量分析表明,术前尿路感染的数量最能预测葡聚糖/透明质酸注射后的感染可能性。接受随访膀胱造影的发热性尿路感染患者中近一半患有反流复发。结论:注射前感染多于3种的患者发生注射后症状性尿路感染的可能性比注射1次有1种感染的患者高8.5倍。右旋糖酐/透明质酸返流后,症状性和发热性感染的总体发生率与输尿管再植入后报告的相似。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号